Top Markets
Coin of the day
Gyre Therapeutics, Inc. Gyre Therapeutics, Inc.

Gyre Therapeutics, Inc.

GYRE
Classement en actions #11143
Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering,... Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
Prix de l'action
$6.61
Dernière synchronisation: 2026-08-28
Capitalisation boursière
$736.94M
Changement (1 jour)
-1.05%
Changement (1 an)
-14.60%
Pays
US
Échange Gyre Therapeutics, Inc. (GYRE)

Catégorie

Ratio P/B pour Gyre Therapeutics, Inc. (GYRE)
Ratio P/B au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Gyre Therapeutics, Inc., le ratio cours/valeur comptable actuel (TTM) est 0. À la fin de 2026, le ratio P/B était de 0.
Historique du ratio P/B pour Gyre Therapeutics, Inc. de 2026 à 2026
Ratio P/B à la fin de chaque année
Année Ratio P/B Changez
Pas assez de données pour les dates fournies.
Ratio P/B pour des entreprises similaires ou concurrentes
Entreprise Ratio P/B Différence de Ratio P/B Pays
6.3419 -
US
6.2413 -
NL
2.5054 -
AU
3.7087 -
US
- -
CH